Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €28.03 EUR
Change Today +0.69 / 2.52%
Volume 0.0
MZN On Other Exchanges
Symbol
Exchange
MZN is not on other exchanges.
As of 3:53 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

medicines company (MZN) Snapshot

Open
€27.33
Previous Close
€27.34
Day High
€28.20
Day Low
€26.79
52 Week High
07/17/15 - €31.23
52 Week Low
10/13/14 - €15.76
Market Cap
1.9B
Average Volume 10 Days
10.0
EPS TTM
--
Shares Outstanding
66.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDICINES COMPANY (MZN)

medicines company (MZN) Related Businessweek News

No Related Businessweek News Found

medicines company (MZN) Details

The Medicines Company provides medicines for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria; Orbactiv for the treatment of acute bacterial skin and skin structure infections; PreveLeak, a mechanical vascular and surgical sealant; ready-to-use formulation of Argatroban for the treatment of thrombosis; and Recothrom, a human recombinant thrombin used as an aid to hemostasis, as well as acute care generic products for acute cardiovascular, surgery and perioperative care, and serious infectious diseases. Its development stage products include Cangrelor for the prevention of platelet activation and aggregation; IONSYS for the short-term management of acute postoperative pain; Raplixa, a dry powder topical formulation of fibrogen and thrombin; and RPX-602 for the treatment of bacterial infections. The company’s products under development also comprise ABP-700, an intravenous anesthetic agent for moderate or deep sedation and general anesthesia in patients undergoing diagnostic or therapeutic procedures; LN-PCSsc for the treatment of hypercholesterolemia; Carbavance, an antibiotic agent for the treatment of hospitalized patients with bacterial infections; and MDCO-216, a novel biologic product to reverse atherosclerotic plaque development and reduce the risk of ischemic events in patients with ACS. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize ALN-PCSsc. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.

727 Employees
Last Reported Date: 03/2/15
Founded in 1996

medicines company (MZN) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $874.6K
President, Chief Financial Officer, Treasurer...
Total Annual Compensation: $642.6K
Chief Accounting Officer and Senior Vice Pres...
Total Annual Compensation: $393.8K
Compensation as of Fiscal Year 2014.

medicines company (MZN) Key Developments

The Medicines Company Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

The Medicines Company reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net revenue of $90,472,000 against $183,774,000 a year ago. Loss from operations was $78,994,000 against $31,886,000 a year ago. Loss before income taxes was $67,837,000 against $28,602,000 a year ago. Net loss was $46,539,000 against $5,174,000 a year ago. Net loss attributable to the company was $46,592,000 or $0.71 per share basic and diluted against $5,157,000 or $0.08 per share basic and diluted a year ago. Net loss attributable to company adjusted was $42,752,000 or $0.65 per share diluted against net income attributable to company adjusted of $20,587,000 or $0.31 per share diluted a year ago. For the six months, the company reported net revenue of $216,988,000 against $361,009,000 a year ago. Loss from operations was $90,698,000 against $17,135,000 a year ago. Loss before income taxes was $57,054,000 against $11,512,000 a year ago. Net loss was $41,533,000 against $10,179,000 a year ago. Net loss attributable to the company was $41,558,000 or $0.63 per share basic and diluted against $10,153,000 or $0.16 per share basic and diluted a year ago. Net loss attributable to company adjusted was $37,076,000 or $0.57 per share diluted against net income attributable to company adjusted of $42,696,000 or $0.64 per share diluted a year ago.

The Medicines Company Announces Distribution Agreement with Sandoz in US

The Medicines Company has signed an agreement with Sandoz Inc. for the distribution of an authorized generic of its anticoagulant, ANGIOMAX, or bivalirudin, for injection, in the US. This agreement with Sandoz, itself a leader in the generics market, helps to ensure that bivalirudin remains a high quality product in this market.

The Medicines Company to Report Q2, 2015 Results on Jul 29, 2015

The Medicines Company announced that they will report Q2, 2015 results at 8:30 AM, US Eastern Standard Time on Jul 29, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MZN:GR €28.03 EUR +0.69

MZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BTG PLC 654.00 GBp +2.50
Impax Laboratories Inc $48.46 USD +0.10
Integra LifeSciences Holdings Corp $64.13 USD +0.13
Krka dd Novo mesto €65.75 EUR +0.10
Skyepharma PLC 280.00 GBp +1.25
View Industry Companies
 

Industry Analysis

MZN

Industry Average

Valuation MZN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.6x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDICINES COMPANY, please visit www.themedicinescompany.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.